OrthoLogic to Webcast Conference Call Discussing Second Quarter 2005 Financial Results on July 26, 2005
July 19 2005 - 5:30PM
PR Newswire (US)
OrthoLogic to Webcast Conference Call Discussing Second Quarter
2005 Financial Results on July 26, 2005 TEMPE, Ariz., July 19
/PRNewswire-FirstCall/ -- OrthoLogic Corp. (NASDAQ:OLGC) announced
today that it will release financial and operating results for the
second quarter of 2005 on Tuesday, July 26, 2005 after the U.S.
markets close. Management will host a conference call and webcast
the same day at 4:30 p.m. EDT (1:30 p.m. PDT). To access the call,
participants may dial 800-289-0544 (domestic) or 913-981-5533
(international) and provide the access code 6064597. A replay of
the call will be available beginning July 26, 2005, at 7:30 p.m.
EDT until August 25, 2005, at 12:59 a.m. EDT. To access the replay,
please dial 888-203-1112 (domestic) or 719-457-0820 (international)
and provide the access code 6064597. Additionally, the conference
call will be webcast on the Investor Relations section of the
Company's website, http://www.orthologic.com/, and can be accessed
by clicking here: OrthoLogic 2Q05 Earnings Webcast. About
OrthoLogic Corp. OrthoLogic is a drug-development company focused
on commercializing several potential therapeutics comprising the
Chrysalin(R) Product Platform, a series of product candidates aimed
at treating traumatic and chronic orthopedic indications in bone
and soft tissue as well as cardiovascular repair and wound healing.
All of these potential products are based on the Chrysalin
synthetic peptide, also known as TP508. OrthoLogic owns an
exclusive license for all worldwide medical indications for the
peptide, and is actively pursuing five orthopedic indications for
Chrysalin. These include fracture repair and spine fusion, which
are in human clinical trials, and cartilage defect repair, which is
in late-stage preclinical trials. Ligament and tendon repair
indications are in the preclinical studies stage. In non-orthopedic
areas, a human clinical trial for chronic diabetic ulcers has been
completed. OrthoLogic's product development pipeline also includes
Chrysalin-based product candidates for dental bone formation and
myocardial revascularization. For more information, please visit
the company's Web site: http://www.orthologic.com/. DATASOURCE:
OrthoLogic Corp. CONTACT: Sherry A. Sturman Chief Financial Officer
of OrthoLogic Corp., +1-602-286-5436; or Melanie Friedman of Stern
Investor Relations, Inc., +1-212-362-1200, for OrthoLogic Corp. Web
site: http://www.orthologic.com/
Copyright
Orthologic (MM) (NASDAQ:OLGC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Orthologic (MM) (NASDAQ:OLGC)
Historical Stock Chart
From Sep 2023 to Sep 2024